Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042

Herbst R. S., Lopes G., Kowalski D. M., Kasahara K., Wu Y., De Castro G., ...More

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11 - 14 December 2019, vol.30, (Summary Text) identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 30
  • City: Geneva
  • Country: Switzerland
  • Istanbul University Affiliated: Yes